Literature DB >> 10084485

Pulmonary cryptococcosis in patients without HIV infection.

J A Aberg1, L M Mundy, W G Powderly.   

Abstract

PURPOSE: To further elucidate the diagnostic and therapeutic approaches to patients with pulmonary cryptococcosis who are not HIV-infected.
SUBJECTS: All of the patients without HIV infection who received care at two Midwest hospitals between January 1986 and February 1996 and had a respiratory isolate of Cryptococcus neoformans.
METHODS: The medical records of the study patients were reviewed for demographic data, host immune status, respiratory symptoms, diagnostic studies, treatment, and follow-up.
RESULTS: Forty-two patient presentations comprised the overall study group. Thirty-six patients (85.7%) had no evidence of dissemination, and six patients (14.3%) had disseminated disease. Seven of the 36 patient presentations were definitive pulmonary cryptococcosis, 15 were presumptive disease, and 14 were colonization with C neoformans. Neither the baseline demographic parameters nor the immune status appeared to discriminate the patients with disease from the patients with colonization. A serum cryptococcal antigen (sCRAG) was positive for 7 of 18 patients, 3 of whom were proven by culture to have a disseminated infection. A negative sCRAG was observed in 11 patients, one of whom had proven dissemination. Fifteen patients underwent a lumbar puncture as part of their evaluation, and cryptococcal meningitis was diagnosed in three of these patients, all of whom had positive blood cultures for C neoformans. The majority of the patients did not receive antifungal therapy.
CONCLUSION: In the majority of the patients, the lung appeared to be the sole organ involved, and a workup for systemic infection was rarely helpful. A positive sCRAG was not specific for dissemination. Antifungal therapy should be reserved for symptomatic patients, for patients with a positive sCRAG, and for patients with underlying immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10084485     DOI: 10.1378/chest.115.3.734

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  39 in total

1.  Cryptococcus infection in tropical Australia.

Authors:  Adam Jenney; Kishan Pandithage; Dale A Fisher; Bart J Currie
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  A typical atypical pneumonia.

Authors:  J Mikhael; S Humphrey; M Jabi; Ad Badley
Journal:  Can J Infect Dis       Date:  2002-01

Review 3.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

4.  Uncommon mycosis in a patient with diabetes.

Authors:  Kuruswamy Thurai Prasad; Inderpaul Singh Sehgal; M R Shivaprakash; Sahajal Dhooria
Journal:  BMJ Case Rep       Date:  2016-02-25

5.  The copper regulon of the human fungal pathogen Cryptococcus neoformans H99.

Authors:  Chen Ding; Jun Yin; Edgar Mauricio Medina Tovar; David A Fitzpatrick; Desmond G Higgins; Dennis J Thiele
Journal:  Mol Microbiol       Date:  2011-08-23       Impact factor: 3.501

6.  Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries.

Authors:  Xin Zhang; Rui Wang; Xiuzhen Di; Bin Liu; Youning Liu
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

7.  Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production.

Authors:  Benjamin J Murdock; Gary B Huffnagle; Michal A Olszewski; John J Osterholzer
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

8.  Pulmonary cryptococcosis: imaging findings in 23 non-AIDS patients.

Authors:  Kyoung Doo Song; Kyung Soo Lee; Man Pyo Chung; O Jung Kwon; Tae Sung Kim; Chin A Yi; Myung Jin Chung
Journal:  Korean J Radiol       Date:  2010-06-21       Impact factor: 3.500

9.  Cryptococcal sepsis in small vessel vasculitis.

Authors:  S Satish; R Rajesh; S Shashikala; G Kurian; V N Unni
Journal:  Indian J Nephrol       Date:  2010-07

10.  Cavitating pneumonia after treatment with infliximab and prednisone.

Authors:  S M Arend; E J Kuijper; C F Allaart; W Hissink Muller; J T Van Dissel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-23       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.